GSK Looks To Long-Acting Therapy To Restore Lead In HIV
Targeting HIV Cure By 2030
Executive Summary
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
You may also be interested in...
Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
A HIV Vaccine Proves Elusive Again As J&J Study Fails
Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.